Bioventus Reaches Milestone with 2 Million DUROLANE® Treatments Worldwide
Bioventus, a global leader in Innovations For Active Healing, is celebrating a milestone and recognizing more than 2 million treatments worldwide with DUROLANE, its single-injection, hyaluronic acid (HA) product used in the treatment of pain associated with osteoarthritis (OA). DUROLANE is the original single injection hyaluronic acid therapy, has helped patients in nearly 30 countries and is a trusted therapy for clinicians in the management of OA.
Proven safe and effective, DUROLANE has more clinical studies than any other US single-injection HA, and has also been proven to provide greater reduction in OA knee pain versus Synvisc-One®.1,2 It has longer lasting pain relief versus a steroid injection, is safe and repeated use of DUROLANE does not increase the incidence of adverse events.3,4
DUROLANE is available in its original 3ml syringe for treatment of large joints and in a 1ml syringe, known as DUROLANE SJ, to enable treatment of small joints.* Both are produced using a natural, safe and proven technology called NASHA ® . This process yields a high molecular weight stabilized HA, which is a naturally occurring molecule that provides lubrication and cushioning in a normal joint.
“The US launch of DUROLANE in 2018 boosted our growth to more than 2 million treatments and we are very proud of this milestone. Still, there are many more patients to reach,” said John Nosenzo, Chief Commercial Officer, Bioventus. “In the US, more than 14 million people are afflicted with knee OA and osteoarthritis overall affects more than 240 million globally.5,6 Returning people to active lifestyles is our commitment to the market and we are pleased that DUROLANE is serving the needs of clinicians and the OA patients they treat.”
About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioventus include offerings for osteoarthritis, surgical and non-surgical bone healing. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the company on LinkedIn and Twitter.
Bioventus, the Bioventus logo, and DUROLANE are registered trademarks of Bioventus LLC. NASHA is a registered trademark. Synvisc-One and Synvisc are registered trademarks of Genzyme Corporation.
*DUROLANE SJ is not available in the US.
Summary of Indication for Use: DUROLANE is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacological therapy or simple analgesics, e.g. acetaminophen. Do not inject DUROLANE in patients with knee joint infections, skin diseases, or other infections in the area of the injection site. Do not administer to patients with known hypersensitivity or allergy to sodium hyaluronate preparations. Risks can include transient pain or swelling at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children. Full prescribing information can be found in product labeling, at www.DUROLANE.com , or by contacting Bioventus Customer Service at 1-800-836-4080.
NOTE: The above indications presented are for the US market; indications may vary by country. Contact your local Bioventus representative or visit www.durolane.com/uk/selection for prescribing information specific to your market.
1. McGrath AF, McGrath AM, Jessop ZM, et al. A comparison of intra-articular hyaluronic acid competitors in the treatment of mild to moderate knee osteoarthritis. J Arthritis. 2013; 2(1):108. doi:10.4172/2167-7921.1000108. 2. DOF RPT-001111 3. Leighton R, Åkermark C, Therrien R, et. al. NASHA hyaluronic acid vs methylprednisolone for knee osteoarthritis: a prospective, multi-centre, randomized, non-inferiority trial. Osteoarthritis Cartilage. 2014; 22(1):17-25. 4. DUROLANE [package insert]. Durham, NC: Bioventus LLC; 2017. 5. Arthritis Foundation. What is osteoarthritis? Accessed February 9, 2019. www.arthritis.org/about-arthritis/types/osteoarthritis/what-is-osteoarthritis.php 6. Hawker GA. Osteoarthritis is a serious disease. Clin Exp Rheumatol. 2019;37 Suppl 120(5):3-6.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200922005067/en/
Contact information
Thomas Hill
919-474-6715
thomas.hill@bioventusglobal.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization29.10.2025 10:00:00 EET | Press release
MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/ MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC) The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education. Optimized 3D Solution for Medical Training and Research The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK. It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software in
NEC to Acquire CSG, Strengthening Its Position as a Global Leader in Digital Transformation29.10.2025 09:44:00 EET | Press release
NEC Corporation (TSE: 6701) (“NEC”) and CSG Systems International, Inc. (NASDAQ: CSGS) (“CSG”) today announced they have entered into a definitive agreement under which NEC will acquire CSG for US$80.70 per share in cash, for a total enterprise value of approximately US$2.9 billion, or JPY438.5 billion, including debt. The transaction price represents a 17.38% premium over CSG’s closing price of US$68.75 on October 28, 2025, and a 23.07% premium to the volume-weighted average price (VWAP) of CSG common stock for the 30 days ending October 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029203825/en/ The transaction strengthens NEC's position as a leader in next-generation digital solutions and accelerates AI and cloud-driven innovation for customers across industries. It will bring together complementary software and services across digital transformation, expanding NEC's software-as-a-service (SaaS) portfolio, c
Recover™ Secures Multi-Year Recycled Cotton Agreement with H&M29.10.2025 09:00:00 EET | Press release
Since early 2024, H&M and Recover™ have collaborated on product development, which now enables scaled commercial introduction of Recover™ mechanically recycled cotton into H&M’s collections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029456063/en/ Recover™ has signed a multi-year agreement with H&M to support the integration of its recycled cotton fiber, RCotton, for use in H&M’s products. Recover™ combines more than 75 years of textile recycling expertise with advanced processes that deliver traceability and consistent quality at an industrial scale, operating five recycling hubs located at the heart of textile production streams in Europe, Asia and the Americas. These capabilities are essential for a global fashion player like H&M Group, where transparency, fiber performance, and reliable supply are crucial to integrating recycled materials. “We are proud to enter into this partnership with H&M Group. Reliable acces
Samsung Bioepis to Commercialize BYOOVIZ ® (ranibizumab) in Europe from January 202629.10.2025 09:00:00 EET | Press release
Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe. We will work closely with Biogen to ensure a seamless transition and the continued delivery of services to our customers and patients in Europe,” said Linda Choi MacDonald, Executive Vice President and Global Head of Commercial, at Samsung Bioepis. “Samsung Bioepis will continue to broaden our reach to patients across Europe by reinforcing our leadership and expertise in biosimilars.” B
Ant Group’s AQ Tops China’s AI-Native Healthcare Apps, Launching New Features for Chronic Disease and Elderly Care29.10.2025 08:28:00 EET | Press release
Ant Group’s AI healthcare service AQ is now among China’s top 7 AI-native apps and the only healthcare app on the list, based on monthly active users, according to the latest report from QuestMobile on AI applications in China. Within this group, AQ achieved the highest compound growth rate of 83.4%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251028871468/en/ Ant Group’s AI healthcare platform AQ introduces new features, including family health record sharing, to support chronic disease management and elderly care. Since its public beta as an Alipay mini-program in September 2024 and official launch as an independent app in China in June 2025, the AQ platform has served 140 million users as of September 2025. It provides more than 100 AI-powered services, including doctor recommendations, medical report analysis, and personalized health guidance. These developments come amid China’s ongoing demographic transformation. By
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom